Concepedia

Author

Donald Pinto

Bristol-Myers Squibb (United States)ORCID

Also Known As

D J Pinto, D Pinto, D. J. P. PINTO, D. J. PINTO, D. J. Pinto, D.J. PINTO, D.J. Pinto, Donald J P Pinto, Donald J Pinto, Donald J. P. Pinto

119

Publications

4.7K

Citations

34

H-Index

64

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Wilmington UniversityDuPont (United States)Bristol-Myers Squibb (Germany)Middlesex Hospital
DP

About

Donald Pinto is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

36

3K

2

Natural Sciences

16

18

1.6K

3

Engineering

2

2

60

4

Health Sciences

2

2

352

5

Public Health

1

1

58

Donald Pinto

×

50

Publications

4.2K

Citations

32

H-Index

YearCitations

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

Nirmala Raghavan, Charles Frost, Zhigang Yu,

Drug Metabolism and Disposition

2008

598

Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.

Robert A. Copeland, Jean Williams, John Giannaras,

Proceedings of the National Academy of Sciences

1994

410

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Stephanie C. Koch,

Journal of Medicinal Chemistry

2007

391

125I-labelled fibrinogen in the diagnosis of deep-vein thrombosis and its correlation with phlebography

David Negus, Donald Pinto, L P Le Quesne,

British journal of surgery

1968

310

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

Pancras C. Wong, Earl J. Crain, Bailong Xin,

Journal of Thrombosis and Haemostasis

2008

299

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han,

Journal of Medicinal Chemistry

2004

188

Spatial gradients and inhibitory summation in the rat whisker barrel system

Joshua C. Brumberg, Donald Pinto, Daniel J. Simons

Journal of Neurophysiology

1996

176

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang,

Journal of Medicinal Chemistry

2001

172

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

Kan He, Joseph M. Luettgen, Donglu Zhang,

European Journal of Drug Metabolism and Pharmacokinetics

2011

95

Structure-Based Design of Novel Guanidine/Benzamidine Mimics:  Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Patrick Y. S. Lam, Charles G. Clark, Renhua Li,

Journal of Medicinal Chemistry

2003

95

Page 1